More 510K approvals for Micro Medical Solutions, one step closer to first Micro Vascular Integrated Platform (mVIP) for BTK delivery
Wilmington, MA April 18, 2016—Micro Medical Solutions announces it has received 510K approval for one of its lead products, the MicroBalloon, a key part of its planned Micro Vascular Integrated Platform (mVIP). “The MicroBalloon offers ultra-low profile design and a microfilament wire for maximum push and optimal support,” says Gregory Sullivan, CEO of Micro Medical […]
510K approvals for MicroGuide, part of the Micro Medical Solutions Micro Vascular Integrated Platform (mVIP)
Wilmington, MA March 16, 2016—Micro Medical Solutions announces it has received 510K approval for one of its key interventional innovations. “The MicroGuide offers a best-in-class 3Fr design with optimal push, support, and stability with enhanced flexibility for segment-leading device deliverability and support,” says Gregory Sullivan, CEO of Micro Medical Solutions.
Wilmington, MA March 14, 2016—Micro Medical Solutions announces it has received European CE Mark approval for two of its key innovations. “This approval paves the way for the final stage of development for our proprietary Micro Vascular Integrated Platform,” said Gregory Sullivan, CEO of Micro Medical Solutions.
Wilmington MA, February 2016—Micro Medical Solutions, a pioneer in interventional innovation in the treatment of critical limb ischemia (CLI), today announced that one of the most respected experts in the treatment of peripheral artery disease (PAD) and CLI, Dr. Jihad Mustapha, M.D., has joined the company as Chief Medical Officer. Dr. Mustapha is a global thought leader for the treatment of patients with CLI, as well as amputation prevention.
Wilmington, MA December 15, 2015—Interventional pioneer Micro Medical Solutions announces the closing on a $3.6 million Series A round of funding for further development and clinical trials for its Below the Knee (BTK) stent platform. CEO Gregory Sullivan commented that “this Series A round allows us to bolster our research and development, quality assurance testing, and regulatory approval processes for our first-in-class technology as we move toward 510K and CE Mark approval for several of our breakthrough minimally invasive products in 2016.”